Patients with predominantly cranial vs isolated extracranial GCA phenotypes present with different patterns of arterial involvement on 18F-FDG PET-CT scans.
AbbVie (NYSE:ABBV) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), ...
JAK inhibitor Rinvoq (upadacitinib) has been backed by the CHMP as a 15mg, once-daily treatment for adults with GCA, an ...
EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis: North Chicago, Illinois Monday, March 3, 2025, 15:00 Hrs [IST] AbbVie annou ...
Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...
Vasculitis is an autoimmune disorder that causes inflammation of the blood vessels. It can affect arteries, veins, and capillaries. This condition causes blood vessel walls to swell, which restricts ...
A key regulatory win could turn this under-the-radar treatment into AbbVie's next billion-dollar success story.
If approved, upadacitinib would be the first and only oral advanced therapy for adults living with GCA. "Giant cell arteritis is an inflammatory disease that, if left untreated, can lead to severe ...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults with giant cell arteritis (GCA).
AVTOZMA® is Celltrion’s twelfth biosimilar to obtain marketing authorization in the European Union. Stay tuned to Big Molecule Watch for more regulatory updates on biosimilars.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback